Semax: The ACTH-Derived Peptide Studied for Cognitive Enhancement and Neuroprotection

Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone. Research suggests it supports cognitive function and neuroprotection through BDNF upregulation and modulation of dopaminergic signalling.

By UAE Peptide Clinic Research Desk

Cognitive performance sits at the centre of almost every wellness goal — productivity, longevity, emotional resilience. Yet the neuroscience of cognitive decline is rarely discussed in the context of peptide therapy. Semax is one of the more rigorously studied neuropeptides, with a body of preclinical and clinical research spanning four decades, and it is now attracting serious interest from longevity-focused physicians beyond its country of origin.

What Is Semax?

Semax is a synthetic heptapeptide — a chain of seven amino acids — derived from a fragment of adrenocorticotropic hormone (ACTH 4–10). Unlike ACTH itself, Semax has no hormonal activity on the adrenal glands. Instead, it was engineered specifically for its effects on the central nervous system, making it a true neuropeptide with a targeted mechanism of action.

Originally developed by the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax was studied extensively for stroke recovery, cognitive impairment, and attention-related presentations. It has been approved in Russia as a nootropic and neuroprotective agent, and the published literature has been subjected to independent review in Western journals.

How Semax Works: The BDNF Connection

The most studied mechanism of Semax is its ability to upregulate brain-derived neurotrophic factor (BDNF) — a protein critical for the growth, maintenance, and survival of neurons. BDNF is often described as the brain's growth hormone, and research suggests that its decline is associated with depression, cognitive impairment, and neurodegeneration.

Preclinical data shows that Semax increases BDNF expression in the hippocampus and frontal cortex — two regions central to memory consolidation and executive function. It also appears to modulate dopaminergic and serotonergic neurotransmission, which may explain the reported improvements in attention, working memory, and mood stability seen in research subjects.

What the Research Suggests

The clinical research on Semax is most robust in the context of ischaemic stroke recovery. A series of controlled trials found that Semax administration in the acute and subacute phases of stroke was associated with improved neurological outcomes and faster functional recovery compared to standard care alone. These findings are significant because they suggest Semax can protect neurons from damage even after injury has occurred — a property known as neuroprotection.

Beyond stroke, smaller studies have examined Semax in healthy adults and in populations with mild cognitive impairment. Research suggests improvements in attention, information processing speed, and short-term memory, though larger randomised controlled trials in healthy populations are still limited. This is an important caveat: the most compelling data relates to pathological states, and extrapolation to performance enhancement in healthy individuals should be viewed with appropriate scientific caution.

The most compelling research on Semax centres on neuroprotection and stroke recovery — contexts in which the stakes of neuronal preservation are highest.

Delivery and Clinical Protocol Considerations

Semax is most commonly administered intranasally, which allows direct transit across the nasal epithelium and into the central nervous system, bypassing hepatic first-pass metabolism. This route is well-studied and is the standard delivery method in the clinical research literature. Some protocols use subcutaneous injection, though intranasal delivery is generally preferred for this peptide.

Protocol design — including dose, frequency, and duration — requires physician oversight. As with all peptides, the right protocol depends on individual goals, baseline neurological status, and concurrent medications. A physician-led assessment, including a baseline cognitive evaluation and relevant bloodwork, is the appropriate starting point.

Is Semax Right for You?

Semax is best suited to individuals focused on cognitive resilience, neuroprotection, or recovery from neurological stress. It is not a stimulant, and its effects tend to be cumulative rather than immediately perceptible — a distinction worth understanding before beginning any protocol. If you are exploring peptide therapy for cognitive or neurological goals, the appropriate first step is a clinical consultation where your history, objectives, and current health status can be properly assessed.

Start with our free quiz to identify which peptide categories may be relevant to your goals, or book a physician consultation to discuss Semax and other neuroendocrine peptides in a clinically supervised setting.